Acacia Pharma Group (ACPGF) Stock Price, News & Analysis

Company Overview

Acacia Pharma Group plc is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for nausea and vomiting in both oncology and perioperative settings. Headquartered in London, the company operates through a U.S. subsidiary that supports its commercial activities in North America. Acacia Pharma’s strategy centers on identifying unmet medical needs in supportive care and bringing forward novel formulations that improve patient outcomes and experience.

The company’s lead products target chemotherapy‐induced and postoperative nausea and vomiting. Its SUSTOL® formulation of prolonged‐release granisetron has been approved for the prevention of chemotherapy‐induced nausea and vomiting following moderately emetogenic chemotherapy. BARHEMSYS® (amisulpride injection) is indicated for the prevention and treatment of postoperative nausea and vomiting and is marketed in the United States through a strategic partnership with a specialty pharmaceutical distributor.

Founded in 2013, Acacia Pharma advanced SUSTOL through clinical development and secured U.S. Food and Drug Administration approval in 2015, followed by BARHEMSYS approval in 2020. The company maintains regulatory and distribution partnerships that facilitate market access in the United States and selected European territories. Acacia Pharma continues to explore lifecycle‐extension programs and additional supportive‐care products to complement its existing portfolio.

Under the leadership of Chief Executive Officer Paul Kavanagh, Acacia Pharma leverages a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial operations. The company’s governance and operational footprint reflect a commitment to building a sustainable specialty pharmaceutical business that addresses critical gaps in supportive oncology care.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.76 to $4.00
• Volume: N/A
• Average Volume: 4,104 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACPGF Stock Analysis - Frequently Asked Questions

How have ACPGF shares performed this year?

Acacia Pharma Group's stock was trading at $0.99 at the beginning of 2025. Since then, ACPGF stock has increased by 0.0% and is now trading at $0.99.

How do I buy shares of Acacia Pharma Group?

Shares of ACPGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceuticals - Major
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ACPGF
• CIK: N/A
• Web: www.acaciapharma.com
• Phone: 44 1223 919760
• Fax: N/A
• Employees: 72
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A